Posted by Michael Wonder on 19 Jan 2021
Taysha Gene Therapies receives rare paediatric disease and orphan drug designations for TSHA-105 for the treatment of epilepsy caused by SLC13A5 deficiency
19 January 2021 - Designations reinforce unmet need for treatment options for patients with rare form of genetic epilepsy.
Taysha Gene Therapies today announced that it has received both rare paediatric disease and orphan drug designations from the U.S. FDA for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy.
